NASDAQ:TNDM - Tandem Diabetes Care Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $33.2509 +1.90 (+6.06 %) (As of 11/15/2018 02:49 PM ET)Previous Close$31.35Today's Range$31.01 - $33.4352-Week Range$2.14 - $52.55Volume1.06 million shsAverage Volume2.43 million shsMarket Capitalization$1.88 billionP/E Ratio-2.58Dividend YieldN/ABeta0.53 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; t:slim X2 with G5 integration; and Tandem Device Updater, a PC and Mac-compatible tool that allows users to update their pump's software. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way to display therapy management data from the pump and supported blood glucose meters for users, their caregivers, and their healthcare providers; t:lock cartridge and infusion set products; and various pump accessories. Its products in development include automated insulin delivery systems; t:slim X2 with Basal IQ; t:slim X2 with control IQ; t:sport insulin delivery system; and connected (mobile) health mobile application. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was founded in 2006 and is headquartered in San Diego, California. Receive TNDM News and Ratings via Email Sign-up to receive the latest news and ratings for TNDM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNDM Previous Symbol CUSIPN/A Webwww.tandemdiabetes.com Phone858-366-6900 Debt Debt-to-Equity RatioN/A Current Ratio2.78 Quick Ratio2.36 Price-To-Earnings Trailing P/E Ratio-2.58 Forward P/E Ratio-24.63 P/E GrowthN/A Sales & Book Value Annual Sales$107.60 million Price / Sales17.73 Cash FlowN/A Price / CashN/A Book Value$2.01 per share Price / Book16.54 Profitability EPS (Most Recent Fiscal Year)($12.87) Net Income$-73,030,000.00 Net Margins-93.07% Return on Equity-204.32% Return on Assets-43.75% Miscellaneous Employees574 Outstanding Shares57,370,000Market Cap$1.88 billion OptionableOptionable Tandem Diabetes Care (NASDAQ:TNDM) Frequently Asked Questions What is Tandem Diabetes Care's stock symbol? Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM." When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work? Tandem Diabetes Care shares reverse split on the morning of Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split. How were Tandem Diabetes Care's earnings last quarter? Tandem Diabetes Care Inc (NASDAQ:TNDM) released its earnings results on Thursday, November, 1st. The medical device company reported ($0.62) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.34) by $0.28. The medical device company had revenue of $46.30 million for the quarter, compared to analysts' expectations of $42.71 million. Tandem Diabetes Care had a negative net margin of 93.07% and a negative return on equity of 204.32%. The firm's quarterly revenue was up 71.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($3.09) earnings per share. View Tandem Diabetes Care's Earnings History. When is Tandem Diabetes Care's next earnings date? Tandem Diabetes Care is scheduled to release their next quarterly earnings announcement on Thursday, March 7th 2019. View Earnings Estimates for Tandem Diabetes Care. What price target have analysts set for TNDM? 12 brokers have issued 12-month price targets for Tandem Diabetes Care's shares. Their predictions range from $5.50 to $60.00. On average, they expect Tandem Diabetes Care's stock price to reach $44.6250 in the next twelve months. This suggests a possible upside of 34.2% from the stock's current price. View Analyst Price Targets for Tandem Diabetes Care. What is the consensus analysts' recommendation for Tandem Diabetes Care? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tandem Diabetes Care. Has Tandem Diabetes Care been receiving favorable news coverage? Media headlines about TNDM stock have been trending somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tandem Diabetes Care earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news headlines about the medical device company a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an effect on the company's share price in the near future. Who are some of Tandem Diabetes Care's key competitors? Some companies that are related to Tandem Diabetes Care include Hill-Rom (HRC), Haemonetics (HAE), Globus Medical (GMED), Insulet (PODD), Penumbra (PEN), Integra Lifesciences (IART), ICU Medical (ICUI), Cantel Medical (CMD), Merit Medical Systems (MMSI), NuVasive (NUVA), Novocure (NVCR), Glaukos (GKOS), Irhythm Technologies (IRTC), Mazor Robotics (MZOR) and Atrion (ATRI). Who are Tandem Diabetes Care's key executives? Tandem Diabetes Care's management team includes the folowing people: Mr. Kim D. Blickenstaff, Pres, CEO & Director (Age 66)Mr. John F. Sheridan, Exec. VP & COO (Age 63)Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 50)Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 45)Ms. Susan M. Morrison, Exec. VP & Chief Admin. Officer (Age 39) Who are Tandem Diabetes Care's major shareholders? Tandem Diabetes Care's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.81%), Frontier Capital Management Co. LLC (2.74%), Redmile Group LLC (1.86%), Ardevora Asset Management LLP (1.62%), Point72 Asset Management L.P. (1.44%) and Eagle Asset Management Inc. (1.38%). Company insiders that own Tandem Diabetes Care stock include Christopher J Twomey, Dick Allen, Kim D Blickenstaff and Richard P Valencia. View Institutional Ownership Trends for Tandem Diabetes Care. Which institutional investors are selling Tandem Diabetes Care stock? TNDM stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Frontier Capital Management Co. LLC, Point72 Asset Management L.P., Wasatch Advisors Inc., Emerald Advisers Inc. PA, Castleark Management LLC, Emerald Mutual Fund Advisers Trust and Essex Investment Management Co. LLC. View Insider Buying and Selling for Tandem Diabetes Care. Which institutional investors are buying Tandem Diabetes Care stock? TNDM stock was purchased by a variety of institutional investors in the last quarter, including Redmile Group LLC, BlackRock Inc., Ardevora Asset Management LLP, Eagle Asset Management Inc., Carillon Tower Advisers Inc., Baillie Gifford & Co., Deutsche Bank AG and Renaissance Technologies LLC. Company insiders that have bought Tandem Diabetes Care stock in the last two years include Christopher J Twomey, Dick Allen, Kim D Blickenstaff and Richard P Valencia. View Insider Buying and Selling for Tandem Diabetes Care. How do I buy shares of Tandem Diabetes Care? Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Tandem Diabetes Care's stock price today? One share of TNDM stock can currently be purchased for approximately $33.2509. How big of a company is Tandem Diabetes Care? Tandem Diabetes Care has a market capitalization of $1.88 billion and generates $107.60 million in revenue each year. The medical device company earns $-73,030,000.00 in net income (profit) each year or ($12.87) on an earnings per share basis. Tandem Diabetes Care employs 574 workers across the globe. What is Tandem Diabetes Care's official website? The official website for Tandem Diabetes Care is http://www.tandemdiabetes.com. How can I contact Tandem Diabetes Care? Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company can be reached via phone at 858-366-6900 or via email at [email protected] MarketBeat Community Rating for Tandem Diabetes Care (NASDAQ TNDM)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 373 (Vote Outperform)Underperform Votes: 375 (Vote Underperform)Total Votes: 748MarketBeat's community ratings are surveys of what our community members think about Tandem Diabetes Care and other stocks. Vote "Outperform" if you believe TNDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNDM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/15/2018 by MarketBeat.com StaffFeatured Article: What is Cost of Debt?